Separate terms with OR to return results that match either term.
 
Clear All
700 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class (Ascending) Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
J9313 Moxetumomab-pasudotox-tdfk Lumoxiti 0.01mg Immunotherapy Drug Antibody Conjugate CD22 No 2018 Oct. 1, 2019 In Use
J9177 Enfortumab vedotin-ejfv Padcev 0.25mg Immunotherapy Drug Antibody Conjugate Nectin-4 No 2019 July 1, 2020 In Use
J9358 Fam-trastuzumab deruxtecan-nxki Enhertu 1mg Immunotherapy Drug Antibody Conjugate HER2, topoisomerase, tetrapeptide No 2019 July 1, 2020 In Use
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan. 1, 2021 No Longer Used
J9317 Sacituzumab govitecan-hziy Trodelvy 2.5mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Jan. 1, 2021 In Use
C9066 Sacituzumab govitecan-hziy Trodelvy 10mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Oct. 1, 2020 Jan. 1, 2021 In Use
J9037 Belantamab mafodontin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 April 1, 2021 In Use
J9309 Polatuzumab Vedotin Polivy 1mg Immunotherapy Drug Antibody Conjugate CD79b No 2019 Jan. 1, 2020 In Use
C9084 Loncastuximab tesirine Zylonta 0.1mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 Sept. 27, 2021 March 25, 2022 In Use
J9273 Tisotumab vedodin-tftv Tivdak 1mg Immunotherapy Drug Antibody Conjugate Tissue factor No 2021 March 25, 2022 In Use
J9359 Loncastuximab tesirine-lpyl Zynlonta 0.075mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 March 25, 2022 In Use
C9146 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 March 17, 2023 July 11, 2023 No Longer Used
J9063 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 July 11, 2023 In Use
C9065 Romidepsin Romidepsin 1mg Chemotherapy Enzyme Inhibetor HDAC No 2020 Jan. 1, 2021 Sept. 27, 2021 No Longer Used
J9032 Belinostat Beleodaq 10 mg Chemotherapy Enzyme Inhibitor HDAC No 2014 Jan. 1, 2016 In Use
NA Enasidenib mesylate Idhifa 50 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Enasidenib mesylate Idhifa 100 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
J8561 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan. 1, 2012 Dec. 31, 2012 No Longer Used
J7527 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan. 1, 2013 In Use
NA idelalisib Zydelig 100 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
NA idelalisib Zydelig 150 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
NA Niraparib Zejula 100 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA olaparib Lynparza 50 mg Chemotherapy Enzyme Inhibitor PARP Yes 2014 In Use
NA Panobinostat Farydak 10 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use

Found 700 results in 2 milliseconds — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.